OncoMatch/Clinical Trials/NCT06184698
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
Is NCT06184698 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including liposomal irinotecan and 5-FU for colorectal cancer.
Treatment: liposomal irinotecan · 5-FU · LV · Bevacizumab — This is a multi-center, single-arm study to investigate the efficacy and safety of liposomal irinotecan+5-FU/LV+ bevacizumab as second-line therapy in metastatic colorectal cancer in Chinese population.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (oxaliplatin) — first-line
First-line treatment with oxaliplatin-based therapy
Cannot have received: topoisomerase inhibitor (irinotecan, liposomal irinotecan)
Previous treatment with irinotecan/liposomal irinotecan
Cannot have received: antineoplastic therapy
Patients who had received any intravenous antineoplastic therapy within 28 days or oral antineoplastic therapy within 14 days before the first dose of study drug
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥90 g/L, WBC≥3.0×10^9/L
Kidney function
serum creatinine ≤1.5 x ULN or creatinine clearance ≥60 mL/min, proteinuria <2+
Liver function
total bilirubin ≤1.5 × ULN, AST, ALP and ALT ≤2.5 x ULN, ≤5 x ULN if liver metastases are present
adequate biological parameters as demonstrated by the following: absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin (Hgb) ≥90 g/L, white blood cell (WBC)≥3.0×10^9/L. Adequate hepatic function as evidenced by total bilirubin ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and alanine aminotransferase (ALT) ≤2.5 x ULN, ≤5 x ULN if liver metastases are present. Adequate renal function as evidenced by serum creatinine (Cr)≤1.5 x ULN or creatinine clearance ≥60 mL/min, proteinuria <2+.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify